From Preclinical Evidence to Early Clinical Studies: Advancing VO659 for Polyglutamine disorders
- Development of VO659: outlining the path from candidate selection through IND-enabling activities and entry into Phase 1/2a studies
- Broader implications of the VO659 program for advancing next-generation oligo therapies targeting CNS disorders
- Beyond VO659: innovating ASO chemistry to improve CNS uptake